Bafna Pharmaceuticals Ltd vs Biocon Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 130.9 as of 05 May 12:17 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Biocon Ltd changed from 66.3 on March 2021 to 40.4 on March 2025 . This represents a CAGR of -9.43% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Biocon Ltd changed from ₹ 49056 crore on March 2021 to ₹ 40964 crore on March 2025 . This represents a CAGR of -3.54% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Biocon Ltd for the Dec '25 is ₹ 4290 crore as compare to the Sep '25 revenue of ₹ 4388 crore. This represent the decline of -2.24% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Biocon Ltd for the Dec '25 is ₹ 657.4 crore as compare to the Sep '25 ebitda of ₹ 916.5 crore. This represent the decline of -28.27% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Biocon Ltd changed from ₹ 861.8 crore to ₹ -51.8 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
Also in the same year, the company had received US funding for proprietary technologies.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Biocon Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Biocon Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 324 Cr while Market cap of Biocon Ltd is 58,417 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Biocon Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Biocon Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Biocon Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹137.0. On the other hand, Biocon Ltd stock price is INR ₹360.4.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Biocon Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Biocon Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.